Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GALR2 | O43603 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16875669 | 0.86 | MDM2 (0.42) | MAPTNPSR1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL31290998 | 0.85 | CRHBP (0.39) | MAPTNPSR1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL31191034 | 0.85 | CRHBP (0.39) | MAPTNPSR1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL14702311 | 0.84 | ALDH1A1 (0.42) | MAPTKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL15549951 | 0.83 | MAPT (0.41) | MAPTNPSR1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL25357966 | 0.80 | ALDH1A1 (0.40) | MAPTNPSR1KMT2ALMNAALDH1A1 | |
| SCHEMBL18973787 | 0.75 | CYP19A1 (0.41) | MAPTNPSR1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL25357971 | 0.72 | CYP19A1 (0.39) | MAPTNPSR1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL12556216 | 0.71 | MAPT (0.41) | MAPTNPSR1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL8512483 | 0.70 | KMT2A (0.45) | MAPTNPSR1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596145-B2 | Heterocyclic flavone derivatives, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190160040-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2019-05-30 | — | — | US | disclosed |
| US-20180280342-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010526-B2 | Heterocyclic flavone derivatives, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2877461-B1 | HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170165225-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-15 | — | — | US | disclosed |
| US-9593125-B2 | Heterocyclic flavone derivatives, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2877461-A1 | HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO | Emory University (US) | 2015-06-03 | — | — | EP | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2014018741-A1 | HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2579870-A2 | TRKB AGONISTS AND METHODS OF USE | Emory University (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280342-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | BDNF, NTRK2, RHOT2 | MAPT 7/4885NPSR1 1886/4885KMT2A 543/4885 |
| US-10010526-B2 | Heterocyclic flavone derivatives, compositions, and methods related thereto | BDNF, NTRK2, RHOT2 | MAPT 7/4885NPSR1 1886/4885KMT2A 543/4885 |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | MAPT 1145/4885NPSR1 103/4885KMT2A 1050/4885 |
| US-20170165225-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | BDNF, NTRK2, RHOT2 | MAPT 7/4885NPSR1 1886/4885KMT2A 543/4885 |
| US-10596145-B2 | Heterocyclic flavone derivatives, compositions, and methods related thereto | BDNF, NTRK2, RHOT2 | MAPT 7/4885NPSR1 1886/4885KMT2A 543/4885 |
| US-20190160040-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | BDNF, NTRK2, RHOT2 | MAPT 7/4885NPSR1 1886/4885KMT2A 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.